Biovitrum AB's (publ) rights issue fully subscribed
The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore.
According to the final results of Biovitrum's rights issue, for which the subscription period ended December 30(th), 2009, 100,628,888 shares, corresponding to approximately 99,84 per cent of the offered shares, were subscribed for with subscription rights. The remaining 0.16 per cent corresponding to 163,744 shares have been subscribed for without subscription rights according to the allocation principles set out in the prospectus published on December 9(th), 2009. The rights issue is therefore fully subscribed and the underwriting and guarantee commitments do not have to be utilized. Notifications regarding allotment of shares subscribed for without subscription rights have been sent to those who have received allottment of shares. Only those who are allotted shares will be notified. Through the rights issue Biovitrum will receive approximately SEK 1,512 million before transaction costs. As a result of the rights issue, the number of shares in the company will increase by 100,792,632 to 151,704,533[1], the number of votes will increase by 100,792,632 to 151,240,506.50 and the share capital will increase by approximately SEK 55,304,601 to approximately SEK 83,239,801. The final day for trading in paid subscribed shares (BTAs) was on December 30(th), 2009. Trading in new shares subscribed for with subscription rights as well as trading in new shares subscribed for without subscription rights is expected to commence on NASDAQ OMX Stockholm on or about January 15(th), 2010. Biovitrum intends to complete the acquisition of Swedish Orphan International Holding AB on January 14(th), 2010. In connection therewith and based on the authorization from the extraordinary sharesholders' meeting on December 4(th), 2009, the board of Biovitrum intends to resolve to issue no more than 58,336,606 shares as partial payment for the acquisition. Trading in the new shares is expected to commence on NASDAQ OMX Stockholm on or about January 20(th), 2010. Accordingly, after completion of the rights issue and the acquisition of Swedish Orphan International Holding AB, the total number of shares in Biovitrum is expected to amount to 210,041,139[2], corresponding to in total 209,577,112.5 votes. -------------------------------------------------------------------------------- [1] Whereof 515,585 series C shares. [2] Whereof 515,585 series C shares. For more information please contact: Göran Arvidson, CFO Biovitrum Phone: +46 70 633 30 42 Erik Kinnman, EVP Investor Relations Biovitrum Phone: +46 73 422 15 40 erik.kinnman@biovitrum.com <mailto:erik.kinnman@biovitrum.com> About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the acquisition of Swedish Orphan International Holding AB). Biovitrum's head office is located in Sweden and the share is listed on NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com <http://www.biovitrum.com/>. Important notice The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. The information in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “Securities Act”). The securities mentioned herein may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States. The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 08:30 a.m CET on January 8(th), 2010.